Abstract
Kaposiform hemangioendothelioma (KHE) is a rare vascular neoplasm frequently associated with the Kasabach-Merritt phenomenon (KMP), a life-threatening consumptive coagulopathy characterized by severe thrombocytopenia. While sirolimus has emerged as a frontline therapy, standardized protocols for managing disease "rebound"—where symptoms flare despite ongoing treatment—are lacking. This report describes the successful management of a rare rebound case in a 10-year-old patient using a multi-modal interventional strategy combining sclero-embolization, local vincristine infusion, and ultrasound-guided microwave ablation.
Introduction
Kaposiform hemangioendothelioma is an aggressive pediatric vascular tumor. Its most dangerous complication, the Kasabach-Merritt phenomenon, occurs when the tumor architecture traps and consumes platelets, leading to dangerously low platelet counts and systemic bleeding risks. Although the mTOR inhibitor sirolimus has significantly improved outcomes for KHE/KMP patients, clinical challenges arise when the disease relapses or "rebounds" during therapy. This case highlights the fragility of remission and the necessity of aggressive, multi-modal intervention when systemic drug therapy fails to maintain control.
Case Presentation
The patient, a 10-year-old female, had been undergoing systemic sirolimus treatment for KHE. Following a brief one-week interruption of her medication due to a respiratory infection, she experienced a severe relapse of KMP symptoms, including painful skin purpura and a drop in platelet count to 49,000/mL (normal range: 100,000–300,000). Despite resuming sirolimus, her condition continued to deteriorate, necessitating a more direct interventional approach.
Multi-Modal Interventional Strategy
To address the refractory rebound, the clinical team implemented a "triple-threat" strategy designed to physically and chemically neutralize the tumor:
- Sclero-embolization: The team targeted the arterial branches supplying the tumor—specifically the internal thoracic, axillary, and intercostal arteries—using a mixture of pingyangmycin iodide oil emulsion and polyvinyl alcohol (PVA) particles to cut off the tumor's blood supply.
- Local Vincristine Infusion: During the embolization procedure, 1.2 mg of vincristine, a chemotherapy agent effective against vascular tumors, was infused directly into the lesion site.
- Microwave Ablation: Under real-time ultrasound monitoring, a microwave ablation needle (15 W) was used to thermally destroy the core tumor lesions. This minimally invasive technique provided immediate physical destruction of the tissue responsible for platelet trapping.
Key Results
The combined interventional approach yielded rapid clinical and hematological recovery. Within four days of the procedure, the patient’s platelet counts and coagulation markers stabilized, and the painful purpura began to resolve significantly.
The patient was discharged six days post-surgery. Follow-up confirmed that the life-threatening consumptive state had been halted, and the patient remained stable on a maintenance regimen of sirolimus and prednisone.
Discussion and Insights
This case provides several critical insights into the management of KHE/KMP:
- Fragility of Remission: The rapid rebound triggered by a mere one-week medication break suggests that mTOR pathway suppression must be strictly and continuously maintained in high-risk patients.
- Synergy in Treatment: When systemic monotherapy (sirolimus) fails, a combination of local devascularization (embolization), localized chemotherapy (vincristine), and physical destruction (microwave ablation) can provide the necessary "reset" for the hematological system.
- Role of Microwave Ablation: While common in solid organ oncology, this case supports microwave ablation as a viable, minimally invasive tool for drug-resistant vascular malformations.
Conclusion
While sirolimus remains a cornerstone of KHE management, clinicians must be prepared for aggressive rebounds. This case demonstrates that a multi-modal interventional approach can successfully resolve life-threatening coagulopathy when standard therapies are insufficient. Further multi-center studies are required to establish formal secondary protocols for KHE/KMP rebound cases.
Summary updated